| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Convertase subtilisin/kexin type 9 preproprotein ELISA Kit; FH3 ELISA Kit; HCHOLA3 ELISA Kit; Hypercholesterolemia autosomal dominant 3 ELISA Kit; LDLCQ1 ELISA Kit; NARC 1 ELISA Kit; NARC-1 ELISA Kit; NARC1 ELISA Kit; Neural apoptosis regulated convertase 1 ELISA Kit; Neural apoptosis-regulated convertase 1 ELISA Kit; PC 9 ELISA Kit; PC9 ELISA Kit; PCSK 9 ELISA Kit; PCSK9 ELISA Kit; PCSK9_HUMAN ELISA Kit; Proprotein convertase 9 ELISA Kit; Proprotein convertase PC9 ELISA Kit; Proprotein convertase subtilisin/kexin type 9 ELISA Kit; PSEC0052 ELISA Kit; Subtilisin/kexin like protease PC9 ELISA Kit; Subtilisin/kexin-like protease PC9 ELISA Kit |
| Assay Time | |
| Assay Type | |
| Detection Range | |
| Detection Wavelength | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | serum, plasma, tissue homogenates |
| Sensitivity | |
| Species | |
| Target | |
| UniProt # |
Background
Proprotein convertase subtilisin/kexin type 9(PCSK9) is a biological molecule commonly studied in metabolism research. It is commonly used as a molecular readout in mechanistic and biomarker-focused studies.
UniProt: Q8NBP7
Biological context
Researchers often monitor Proprotein convertase subtilisin/kexin type 9(PCSK9) in serum, plasma, and tissue homogenates to better understand themes such as energy homeostasis, glucose and lipid metabolism, and insulin sensitivity and endocrine regulation. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.
Interpreting changes in measured levels
Depending on sample matrix and study design, increases or decreases in Proprotein convertase subtilisin/kexin type 9(PCSK9) may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, insulin, adipokines, lipid-transport proteins, and stress-related enzymes) and by keeping pre-analytical variables consistent across groups.
Nomenclature
In publications and databases, Proprotein convertase subtilisin/kexin type 9(PCSK9) may also appear under names such as Convertase subtilisin/kexin type 9 preproprotein and FH3. When comparing studies, confirm that the reported analyte refers to the same molecule and species context.
Why ELISA data are widely used
ELISA is a common approach for quantitative measurement of proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that Proprotein convertase subtilisin/kexin type 9(PCSK9) participates in.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
PCSK9 联合乳酸及 SOFA 评分对脓毒症患者死亡风险的预测价值
严妍, 邓紫薇, 仇成凤,天津医药,2025
PCSK9 regulates myofibroblast transformation through the JAK2/STAT3 pathway to regulate fibrosis after myocardial infarction
H Bao,Biochemical pharmacology,2023
Proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with diffuse systemic sclerosis: A marker of disease activity and severe disease manifestations with potential therapeutic implementations
J Artin,Arch Rheumatol,2022
Effects of statins on the inducible degrader of low-density lipoprotein receptor in familial hypercholesterolemia
MLY Chan,Endocrine connections,2022
Interaction between serum endotoxemia and proprotein convertase subtilisin/kexin 9 (PCSK9) in patients with atrial fibrillation: A post-hoc analysis from the ATHERO-AF cohort
Daniele Pastori, et al,Atherosclerosis,2019
Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
Wang Y. et al,Cardiovasc Diabetol.,2016
Combined therapy with Xuezhikang and low-dose rosuvastatin provides an effective and safe therapeutic strategy for dyslipidemic patients
Min Wang. et al,Clinical Lipidology,2015
Assessment of left ventricular function by tissue Doppler echocardiography in pediatric chronic kidney disease
Dogan CS. et al,Ren Fail,2015